DALLAS--(BUSINESS WIRE)--Secretome Therapeutics, a biotechnology company developing first-in-class therapeutics derived from neonatal mesenchymal stem cells (nMSC) for the treatment of underserved diseases, today announced the appointment of Deepa Prasad as Chief Financial Officer.
"Deepa brings a wealth of knowledge through her combination of investment banking, operations, and venture capital experience in the life science industry," said Vinny Jindal, President and Chief Executive Officer of Secretome Therapeutics. "Deepa’s history assisting companies in financings, partnerships, and corporate strategy will be invaluable as we advance our therapies into clinical trials, and we are thrilled to have her on our team.”
"I am truly excited to be joining Secretome at this pivotal time in the company’s history. I believe that secretomes represent a true breakthrough in the field of cell-based therapy, and I look forward to helping Secretome transform the way we treat diseases," said Ms. Prasad.
Ms. Prasad brings more than 20 years of financial and operational expertise. She most recently served as President and CEO of vTv Therapeutics where she refocused operations, secured research initiation and helped raise $35M in financing. Previous to vTv, she was General Partner at WestRiver Group where she led healthcare investments in numerous companies, including Design Therapeutics. Ms. Prasad has also held senior positions at numerous public and private companies, including Blue Shield, Optum, and Coherus Biosciences. She began her career in biotech investment banking executing private placements and buy-side/sell-side M&A. She holds an M.B.A. from the Kellogg School of Management at Northwestern University and a B.S. in Business Administration from UC Berkeley.
She currently serves on the Board of Directors at Design Therapeutics and as Executive Director of the Robinson Life Sciences, Business and Entrepreneurship Program at UC Berkeley.
About Secretome Therapeutics
Secretome Therapeutics is developing a platform of first-in-class therapeutics derived from neonatal mesenchymal stem cells (nMSC) for the treatment and prevention of underserved diseases. Our lead product, STM-21, is a novel secretome in development for adult and pediatric forms of heart failure, and our pipeline includes novel secretomes in development for neurodegenerative and dermatological diseases.
